Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchDornase alfaDornase alfa (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

 

Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial

Porter et al., eLife, doi:10.7554/eLife.87030.4, COVASE, NCT04359654, Jul 2024
Mortality, COVASE -130% Improvement Relative Risk Mortality, inc. non-rando.. 53% Discharge, COVASE 10% Dornase alfa  COVASE  LATE TREATMENT  RCT Is late treatment with dornase alfa beneficial for COVID-19? RCT 99 patients in the United Kingdom (June 2020 - October 2021) Trial underpowered to detect differences c19early.org Porter et al., eLife, July 2024 Favorsdornase alfa Favorscontrol 0 0.5 1 1.5 2+
RCT 99 hospitalized COVID-19 patients showing significantly reduced C-reactive protein (CRP) levels and length of hospital stay with nebulized dornase alfa treatment in addition to standard of care (dexamethasone). Authors combine the randomized patients with retrospective patients using matching that does not match for COVID-19 severity. Dornase alfa was associated with a 33% reduction in CRP, a 63% higher chance of discharge at any timepoint up to 35 days, and increased lymphocyte counts. There was a trend towards reduced mortality which was not statistically significant.
Standard of Care (SOC) for COVID-19 in the study country, the United Kingdom, is very poor with very low average efficacy for approved treatments1. The United Kingdom focused on expensive high-profit treatments, approving only one low-cost treatment, which required a prescription and had limited adoption. The high-cost prescription treatment strategy reduces the probability of treatment—especially early—due to access and cost barriers, and eliminates complementary and synergistic benefits seen with many low-cost treatments.
risk of death, 130.0% higher, RR 2.30, p = 1.00, treatment 1 of 30 (3.3%), control 0 of 9 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), COVASE randomized patients.
risk of death, 53.0% lower, HR 0.47, p = 0.49, treatment 30, control 69, including non-randomized patients.
risk of no hospital discharge, 10.0% lower, RR 0.90, p = 1.00, treatment 3 of 30 (10.0%), control 1 of 9 (11.1%), NNT 90, COVASE randomized patients.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Porter et al., 16 Jul 2024, Randomized Controlled Trial, United Kingdom, peer-reviewed, mean age 56.8, 25 authors, study period June 2020 - October 2021, trial NCT04359654 (history) (COVASE). Contact: joanna.porter@ucl.ac.uk, veni.p@crick.ac.uk.
Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial
Joanna C Porter, Jamie Inshaw, Vincente Joel Solis, Emma Denneny, Rebecca Evans, Mia I Temkin, Nathalia De Vasconcelos, Iker Valle Aramburu, Dennis Hoving, Donna Basire, Tracey Crissell, Jesusa Guinto, Alison Webb, Hanif Esmail, Victoria Johnston, Anna Last, Thomas Rampling, Lena Lippert, Elisa Theresa Helbig, Florian Kurth, Bryan Williams, Aiden Flynn, Pauline T Lukey, Veronique Birault, Venizelos Papayannopoulos
eLife, doi:10.7554/elife.87030
Background: Prinflammatory extracellular chromatin from neutrophil extracellular traps (NETs) and other cellular sources is found in COVID-19 patients and may promote pathology. We determined whether pulmonary administration of the endonuclease dornase alfa reduced systemic inflammation by clearing extracellular chromatin. Methods: Eligible patients were randomized (3:1) to the best available care including dexamethasone (R-BAC) or to BAC with twice-daily nebulized dornase alfa (R-BAC + DA) for seven days or until discharge. A 2:1 ratio of matched contemporary controls (CC-BAC) provided additional comparators. The primary endpoint was the improvement in C-reactive protein (CRP) over time, analyzed using a repeated-measures mixed model, adjusted for baseline factors. Results: We recruited 39 evaluable participants: 30 randomized to dornase alfa (R-BAC +DA), 9 randomized to BAC (R-BAC), and included 60 CC-BAC participants. Dornase alfa was well tolerated and reduced CRP by 33% compared to the combined BAC groups (T-BAC). Least squares (LS) mean post-dexamethasone CRP fell from 101.9 mg/L to 23.23 mg/L in R-BAC +DA participants versus a 99.5 mg/L to 34.82 mg/L reduction in the T-BAC group at 7 days; p=0.01. The anti-inflammatory effect of dornase alfa was further confirmed with subgroup and sensitivity analyses on randomised participants only, mitigating potential biases associated with the use of CC-BAC participants. Dornase alfa increased live discharge rates by 63% (HR 1.63, 95% CI 1.01-2.61, p=0.03), increased lymphocyte counts (LS mean: 1.08 vs 0.87, p=0.02) and reduced circulating cf-DNA and the coagulopathy marker D-dimer (LS mean: 570.78 vs 1656.96 μg/mL, p=0.004). Conclusions: Dornase alfa reduces pathogenic inflammation in COVID-19 pneumonia, demonstrating the benefit of cost-effective therapies that target extracellular chromatin.
Stone, Emma Wall. T8 Nursing Staff: Adam Cureton-Griffiths, Amy Mann, Laura Nichols, Pantelis Savvides. NOCRI Respiratory Translational Research Collaboration: Chris Brightling, Jane Davies, Ratko Djukanovic, Liam Heeney, Ling-Pei Ho, Alex Horsley, Tracy Hussell, Stefan Marciniak, Lorcan McGarvey, Thomas Wilkinson. Pari/Roche Products Limited/LifeArc: Mal Apter, Ruth Davies, Ciara O'Brien, Pauline Stasiak, Davia Viellec. This work was supported by LifeArc (UCL-UCLH132333), UCL, Breathing Matters and the Francis Crick Institute which receives its core funding from the UK Medical Research Council (FC0010129), Cancer Research UK (FC0010129) and the Wellcome Trust (FC0010129). The study was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. VJS and DB are funded by the NIHR University College London Hospitals Biomedical Research Centre. IVA was funded by an EMBO LTF (ALTF 113-2019) . Dornase alfa was provided by Roche Products Limited and nebulizers were donated by PARI. Disclosure forms provided by the authors are available with the full text of the published article. ICH 1996) . Healthy donor plasma was isolated from anonymized consenting healthy adult volunteers, using protocols approved by the Francis Crick Institute ethics board and in accordance with the Human Tissue Act 2004. A total of 6 events were reported, with 2 in the R-BAC and 4 in the R-BAC +DA groups. Additional..
References
Aramburu, Hoving, Vernardis, Tin, Ioannou et al., Functional proteomic profiling links deficient DNA clearance with increased mortality in individuals with severe COVID-19 pneumonia, Immunity, doi:10.1016/j.immuni.2022.11.007
Cortjens, De Jong, Bonsing, Van Woensel, Antonis et al., Local dornase alfa treatment reduces NETs-induced airway obstruction during severe RSV infection, Thorax, doi:10.1136/thoraxjnl-2017-210289
Cui, Merritt, Assa, Mustehsan, Chung et al., Early and significant reduction in C-reactive protein levels after corticosteroid therapy is associated with reduced mortality in patients with COVID-19, Journal of Hospital Medicine, doi:10.12788/jhm.3560
Fisher, Mohanty, Karlsson, Khademi, Malmström et al., Proteome profiling of recombinant dnase therapy in reducing NETs and aiding recovery in COVID-19 patients, Molecular & Cellular Proteomics, doi:10.1016/j.mcpro.2021.100113
Fisher, Veenith, Slade, Gaskell, Rowland et al., Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial, The Lancet. Respiratory Medicine, doi:10.1016/S2213-2600(21)00460-4
Galván-Román, Sc, Vallejo, Jiménez, Sánchez-Alonso et al., IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study, The Journal of Allergy and Clinical Immunology, doi:10.1016/j.jaci.2020.09.018
Han, Ma, Li, Liu, Zhao et al., Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors, Emerging Microbes & Infections, doi:10.1080/22221751.2020.1770129
Herold, Jurinovic, Arnreich, Lipworth, Hellmuth et al., Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19, The Journal of Allergy and Clinical Immunology, doi:10.1016/j.jaci.2020.05.008
Holliday, Earhart, Alnijoumi, Krvavac, Allen et al., Non-randomized trial of dornase alfa for acute respiratory distress syndrome secondary to covid-19, Frontiers in Immunology, doi:10.3389/fimmu.2021.714833
Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in hospitalized patients with Covid-19, The New England Journal of Medicine, doi:10.1056/NEJMoa2021436
Ioannou, Hoving, Aramburu, Temkin, Vasconcelos et al., Microbe capture by splenic macrophages triggers sepsis via T cell-death-dependent neutrophil lifespan shortening, Nature Communications, doi:10.1038/s41467-022-32320-1
Konstan, Ratjen, Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis, Journal of Cystic Fibrosis, doi:10.1016/j.jcf.2011.10.003
Kurth, Roennefarth, Thibeault, Corman, Müller-Redetzky et al., Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19), Infection, doi:10.1007/s15010-020-01464-x
Lazarus, Wagener, Recombinant human Deoxyribonuclease, doi:10.1007/978-3-030-00710-2
Liu, Li, Xu, Wu, Luo et al., Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19, Journal of Clinical Virology, doi:10.1016/j.jcv.2020.104370
Luo, Zhou, Yan, Guo, Wang et al., Prognostic value of c-reactive protein in patients with coronavirus 2019, Clinical Infectious Diseases, doi:10.1093/cid/ciaa641
Malik, Patel, Mehta, Patel, Kelkar et al., Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis, BMJ Evidence-Based Medicine, doi:10.1136/bmjebm-2020-111536
Mcardle, Mcmillan, Sattar, Wallace, Underwood, The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease, British Journal of Cancer, doi:10.1038/sj.bjc.6602211
Messner, Demichev, Wendisch, Michalick, White et al., Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection, Cell Systems, doi:10.1016/j.cels.2020.05.012
Mueller, Tamura, Crowley, Degrado, Haider et al., Inflammatory biomarker trends predict respiratory decline in COVID-19 patients, Cell Reports. Medicine, doi:10.1016/j.xcrm.2020.100144
Okur, Yalcin, Tastan, Demir, Yurtsever et al., Preliminary report of invitro and invivo effectiveness of dornase alfa on SARS-CoV-2 infection, New Microbes and New Infections, doi:10.1016/j.nmni.2020.100756
Papayannopoulos, Neutrophil extracellular traps in immunity and disease, Nature Reviews, doi:10.1038/nri.2017.105
Papayannopoulos, Staab, Zychlinsky, Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving DNase therapy, PLOS ONE, doi:10.1371/journal.pone.0028526
Pillai, Molony, Martinod, Dong, Pang et al., Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease, Science, doi:10.1126/science.aaf3926
Radermecker, Detrembleur, Guiot, Cavalier, Henket et al., Neutrophil extracellular traps infiltrate the lung airway,interstitial, and vascular compartments in severe COVID-19, Journal of Experimental Medicine, doi:10.1084/jem.20201012
Siddiqi, Mehra, COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal, The Journal of Heart and Lung Transplantation, doi:10.1016/j.healun.2020.03.012
Smilowitz, Kunichoff, Garshick, Shah, Pillinger et al., C-reactive protein and clinical outcomes in patients with COVID-19, European Heart Journal, doi:10.1093/eurheartj/ehaa1103
Thoracic, 2000 Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement, American Journal of Respiratory and Critical Care Medicine, doi:10.1164/ajrccm.161.2.ats3-00
Tornling, Batta, Porter, Williams, Bengtsson et al., Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial, EClinicalMedicine, doi:10.1016/j.eclinm.2021.101152
Tsourouktsoglou, Warnatsch, Ioannou, Hoving, Wang et al., Histones, DNA, and citrullination promote neutrophil extracellular trap inflammation by regulating the localization and activation of TLR4, Cell Reports, doi:10.1016/j.celrep.2020.107602
Ullah, Basyal, Tariq, Almas, Saeed et al., Lymphocyte-to-C-reactive protein ratio: a novel predictor of adverse outcomes in COVID-19, Journal of Clinical Medicine Research, doi:10.14740/jocmr4227
Villoteau, Asfar, Otekpo, Loison, Gautier et al., Elevated C-reactive protein in early COVID-19 predicts worse survival among hospitalized geriatric patients, PLOS ONE, doi:10.1371/journal.pone.0256931
Weber, Chau, Egeblad, Barnes, Janowitz, Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series, Molecular Medicine, doi:10.1186/s10020-020-00215-w
Xu, Zhang, Monestier, Esmon, Esmon, Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury, Journal of Immunology, doi:10.4049/jimmunol.1003930
Xu, Zhang, Pelayo, Monestier, Ammollo et al., Extracellular histones are major mediators of death in sepsis, Nature Medicine, doi:10.1038/nm.2053
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Zuo, Yalavarthi, Shi, Gockman, Zuo et al., Neutrophil extracellular traps in COVID-19, JCI Insight, doi:10.1172/jci.insight.138999
DOI record: { "DOI": "10.7554/elife.87030.4", "ISSN": [ "2050-084X" ], "URL": "http://dx.doi.org/10.7554/eLife.87030.4", "abstract": "<jats:sec id=\"abs1\"><jats:title>Background:</jats:title><jats:p>Prinflammatory extracellular chromatin from neutrophil extracellular traps (NETs) and other cellular sources is found in COVID-19 patients and may promote pathology. We determined whether pulmonary administration of the endonuclease dornase alfa reduced systemic inflammation by clearing extracellular chromatin.</jats:p></jats:sec><jats:sec id=\"abs2\"><jats:title>Methods:</jats:title><jats:p>Eligible patients were randomized (3:1) to the best available care including dexamethasone (R-BAC) or to BAC with twice-daily nebulized dornase alfa (R-BAC + DA) for seven days or until discharge. A 2:1 ratio of matched contemporary controls (CC-BAC) provided additional comparators. The primary endpoint was the improvement in C-reactive protein (CRP) over time, analyzed using a repeated-measures mixed model, adjusted for baseline factors.</jats:p></jats:sec><jats:sec id=\"abs3\"><jats:title>Results:</jats:title><jats:p>We recruited 39 evaluable participants: 30 randomized to dornase alfa (R-BAC +DA), 9 randomized to BAC (R-BAC), and included 60 CC-BAC participants. Dornase alfa was well tolerated and reduced CRP by 33% compared to the combined BAC groups (T-BAC). Least squares (LS) mean post-dexamethasone CRP fell from 101.9 mg/L to 23.23 mg/L in R-BAC +DA participants versus a 99.5 mg/L to 34.82 mg/L reduction in the T-BAC group at 7 days; p=0.01. The anti-inflammatory effect of dornase alfa was further confirmed with subgroup and sensitivity analyses on randomised participants only, mitigating potential biases associated with the use of CC-BAC participants. Dornase alfa increased live discharge rates by 63% (HR 1.63, 95% CI 1.01–2.61, p=0.03), increased lymphocyte counts (LS mean: 1.08 vs 0.87, p=0.02) and reduced circulating cf-DNA and the coagulopathy marker D-dimer (LS mean: 570.78 vs 1656.96 μg/mL, p=0.004).</jats:p></jats:sec><jats:sec id=\"abs4\"><jats:title>Conclusions:</jats:title><jats:p>Dornase alfa reduces pathogenic inflammation in COVID-19 pneumonia, demonstrating the benefit of cost-effective therapies that target extracellular chromatin.</jats:p></jats:sec><jats:sec id=\"abs5\"><jats:title>Funding:</jats:title><jats:p>LifeArc, Breathing Matters, The Francis Crick Institute (CRUK, Medical Research Council, Wellcome Trust).</jats:p></jats:sec><jats:sec id=\"abs6\"><jats:title>Clinical trial number:</jats:title><jats:p><jats:related-object document-id=\"NCT04359654\" document-id-type=\"clinical-trial-number\" id=\"RO1\" source-id=\"ClinicalTrials.gov\" source-id-type=\"registry-name\" source-type=\"clinical-trials-registry\" xlink:href=\"https://clinicaltrials.gov/show/NCT04359654\">NCT04359654</jats:related-object>.</jats:p></jats:sec>", "alternative-id": [ "10.7554/eLife.87030.4" ], "assertion": [ { "group": { "name": "peer_review_taxonomy" }, "label": "Peer review transparency", "name": "peer_review_transparency", "value": "single anonymised" }, { "group": { "name": "peer_review_taxonomy" }, "label": "Peer review interaction", "name": "peer_review_interaction", "value": "other reviewer(s), editor" }, { "group": { "name": "peer_review_taxonomy" }, "label": "Peer review published", "name": "peer_review_published", "value": "review summaries, review reports, author/editor communication, reviewer identities reviewer opt in, editor identities" }, { "group": { "name": "post_publication_commenting" }, "label": "Post publication commenting", "name": "post_publication_commenting", "value": "open (sign in with ORCID iD required)" } ], "author": [ { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/02jx3x895", "id-type": "ROR" } ], "name": "UCL Respiratory, University College London", "place": [ "London, United Kingdom" ] }, { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/042fqyp44", "id-type": "ROR" } ], "name": "University College London Hospitals NHS Trust", "place": [ "London, United Kingdom" ] } ], "family": "Porter", "given": "Joanna C", "sequence": "first" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/04dtdfx84", "id-type": "ROR" } ], "name": "Exploristics", "place": [ "Belfast, Ireland" ] } ], "family": "Inshaw", "given": "Jamie", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/042fqyp44", "id-type": "ROR" } ], "name": "University College London Hospitals NHS Trust", "place": [ "London, United Kingdom" ] } ], "family": "Solis", "given": "Vincente Joel", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/02jx3x895", "id-type": "ROR" } ], "name": "UCL Respiratory, University College London", "place": [ "London, United Kingdom" ] }, { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/042fqyp44", "id-type": "ROR" } ], "name": "University College London Hospitals NHS Trust", "place": [ "London, United Kingdom" ] } ], "family": "Denneny", "given": "Emma", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/042fqyp44", "id-type": "ROR" } ], "name": "University College London Hospitals NHS Trust", "place": [ "London, United Kingdom" ] } ], "family": "Evans", "given": "Rebecca", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/04tnbqb63", "id-type": "ROR" } ], "name": "Antimicrobial Defence Lab, The Francis Crick Institute", "place": [ "London, United Kingdom" ] } ], "family": "Temkin", "given": "Mia I", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/04tnbqb63", "id-type": "ROR" } ], "name": "Antimicrobial Defence Lab, The Francis Crick Institute", "place": [ "London, United Kingdom" ] } ], "family": "De Vasconcelos", "given": "Nathalia", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/04tnbqb63", "id-type": "ROR" } ], "name": "Antimicrobial Defence Lab, The Francis Crick Institute", "place": [ "London, United Kingdom" ] } ], "family": "Aramburu", "given": "Iker Valle", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/04tnbqb63", "id-type": "ROR" } ], "name": "Antimicrobial Defence Lab, The Francis Crick Institute", "place": [ "London, United Kingdom" ] } ], "family": "Hoving", "given": "Dennis", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/02jx3x895", "id-type": "ROR" } ], "name": "UCL Respiratory, University College London", "place": [ "London, United Kingdom" ] } ], "family": "Basire", "given": "Donna", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/042fqyp44", "id-type": "ROR" } ], "name": "University College London Hospitals NHS Trust", "place": [ "London, United Kingdom" ] } ], "family": "Crissell", "given": "Tracey", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/042fqyp44", "id-type": "ROR" } ], "name": "University College London Hospitals NHS Trust", "place": [ "London, United Kingdom" ] } ], "family": "Guinto", "given": "Jesusa", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/042fqyp44", "id-type": "ROR" } ], "name": "University College London Hospitals NHS Trust", "place": [ "London, United Kingdom" ] } ], "family": "Webb", "given": "Alison", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/042fqyp44", "id-type": "ROR" } ], "name": "University College London Hospitals NHS Trust", "place": [ "London, United Kingdom" ] }, { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/0187kwz08", "id-type": "ROR" } ], "name": "National Institute for Health Research, University College London Hospital Biomedical Research Centre", "place": [ "London, United Kingdom" ] } ], "family": "Esmail", "given": "Hanif", "sequence": "additional" }, { "ORCID": "http://orcid.org/0009-0004-3006-8441", "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/042fqyp44", "id-type": "ROR" } ], "name": "University College London Hospitals NHS Trust", "place": [ "London, United Kingdom" ] }, { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/0187kwz08", "id-type": "ROR" } ], "name": "National Institute for Health Research, University College London Hospital Biomedical Research Centre", "place": [ "London, United Kingdom" ] } ], "authenticated-orcid": true, "family": "Johnston", "given": "Victoria", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/042fqyp44", "id-type": "ROR" } ], "name": "University College London Hospitals NHS Trust", "place": [ "London, United Kingdom" ] }, { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/00a0jsq62", "id-type": "ROR" } ], "name": "Clinical Research Department, London School of Hygiene and Tropical Medicine", "place": [ "London, United Kingdom" ] } ], "family": "Last", "given": "Anna", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/042fqyp44", "id-type": "ROR" } ], "name": "University College London Hospitals NHS Trust", "place": [ "London, United Kingdom" ] }, { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/0187kwz08", "id-type": "ROR" } ], "name": "National Institute for Health Research, University College London Hospital Biomedical Research Centre", "place": [ "London, United Kingdom" ] } ], "family": "Rampling", "given": "Thomas", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/001w7jn25", "id-type": "ROR" } ], "name": "Charité – Universitätsmedizin Berlin, Department of Infectious Diseases and Respiratory Medicine", "place": [ "Berlin, Germany" ] } ], "family": "Lippert", "given": "Lena", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/001w7jn25", "id-type": "ROR" } ], "name": "Charité – Universitätsmedizin Berlin, Department of Infectious Diseases and Respiratory Medicine", "place": [ "Berlin, Germany" ] } ], "family": "Helbig", "given": "Elisa Theresa", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/001w7jn25", "id-type": "ROR" } ], "name": "Charité – Universitätsmedizin Berlin, Department of Infectious Diseases and Respiratory Medicine", "place": [ "Berlin, Germany" ] } ], "family": "Kurth", "given": "Florian", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/042fqyp44", "id-type": "ROR" } ], "name": "University College London Hospitals NHS Trust", "place": [ "London, United Kingdom" ] }, { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/0187kwz08", "id-type": "ROR" } ], "name": "National Institute for Health Research, University College London Hospital Biomedical Research Centre", "place": [ "London, United Kingdom" ] } ], "family": "Williams", "given": "Bryan", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/04dtdfx84", "id-type": "ROR" } ], "name": "Exploristics", "place": [ "Belfast, Ireland" ] } ], "family": "Flynn", "given": "Aiden", "sequence": "additional" }, { "affiliation": [ { "name": "Target to Treatment Consulting Ltd", "place": [ "Stevenage, United Kingdom" ] } ], "family": "Lukey", "given": "Pauline T", "sequence": "additional" }, { "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/04tnbqb63", "id-type": "ROR" } ], "name": "Translation, The Francis Crick Institute", "place": [ "London, United Kingdom" ] } ], "family": "Birault", "given": "Veronique", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-3741-8190", "affiliation": [ { "id": [ { "asserted-by": "publisher", "id": "https://ror.org/04tnbqb63", "id-type": "ROR" } ], "name": "Antimicrobial Defence Lab, The Francis Crick Institute", "place": [ "London, United Kingdom" ] } ], "authenticated-orcid": true, "family": "Papayannopoulos", "given": "Venizelos", "sequence": "additional" } ], "clinical-trial-number": [ { "clinical-trial-number": "nct04359654", "registry": "10.18810/clinical-trials-gov" } ], "container-title": "eLife", "content-domain": { "crossmark-restriction": false, "domain": [ "elifesciences.org" ] }, "created": { "date-parts": [ [ 2024, 7, 16 ] ], "date-time": "2024-07-16T00:00:53Z", "timestamp": 1721088053000 }, "deposited": { "date-parts": [ [ 2024, 7, 16 ] ], "date-time": "2024-07-16T00:01:06Z", "timestamp": 1721088066000 }, "funder": [ { "DOI": "10.13039/100012357", "award": [ "UCL-UCLH132333" ], "doi-asserted-by": "publisher", "id": [ { "asserted-by": "publisher", "id": "10.13039/100012357", "id-type": "DOI" } ], "name": "LifeArc" }, { "DOI": "10.13039/100010438", "award": [ "FC0010129" ], "doi-asserted-by": "publisher", "id": [ { "asserted-by": "publisher", "id": "10.13039/100010438", "id-type": "DOI" } ], "name": "Francis Crick Institute" }, { "DOI": "10.13039/501100000765", "award": [ "Breathing Matters" ], "doi-asserted-by": "publisher", "id": [ { "asserted-by": "publisher", "id": "10.13039/501100000765", "id-type": "DOI" } ], "name": "University College London" }, { "DOI": "10.13039/501100012621", "doi-asserted-by": "publisher", "id": [ { "asserted-by": "publisher", "id": "10.13039/501100012621", "id-type": "DOI" } ], "name": "NIHR University College London Hospitals Biomedical Research Centre" }, { "DOI": "10.13039/100004410", "award": [ "ALTF 113–2019" ], "doi-asserted-by": "publisher", "id": [ { "asserted-by": "publisher", "id": "10.13039/100004410", "id-type": "DOI" } ], "name": "European Molecular Biology Organization" } ], "indexed": { "date-parts": [ [ 2024, 7, 17 ] ], "date-time": "2024-07-17T00:24:51Z", "timestamp": 1721175891682 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 7, 16 ] ] }, "language": "en", "license": [ { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 7, 16 ] ], "date-time": "2024-07-16T00:00:00Z", "timestamp": 1721088000000 } }, { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "am", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 7, 16 ] ], "date-time": "2024-07-16T00:00:00Z", "timestamp": 1721088000000 } }, { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 7, 16 ] ], "date-time": "2024-07-16T00:00:00Z", "timestamp": 1721088000000 } } ], "link": [ { "URL": "https://cdn.elifesciences.org/articles/87030/elife-87030-v1.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://cdn.elifesciences.org/articles/87030/elife-87030-v1.xml", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://elifesciences.org/articles/87030", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "4374", "original-title": [], "prefix": "10.7554", "published": { "date-parts": [ [ 2024, 7, 16 ] ] }, "published-online": { "date-parts": [ [ 2024, 7, 16 ] ] }, "publisher": "eLife Sciences Publications, Ltd", "reference": [ { "DOI": "10.1164/ajrccm.161.2.ats3-00", "article-title": "Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement", "author": "American Thoracic Society", "doi-asserted-by": "publisher", "first-page": "646", "journal-title": "American Journal of Respiratory and Critical Care Medicine", "key": "bib1", "volume": "161", "year": "2000" }, { "DOI": "10.1016/j.immuni.2022.11.007", "article-title": "Functional proteomic profiling links deficient DNA clearance with increased mortality in individuals with severe COVID-19 pneumonia", "author": "Aramburu", "doi-asserted-by": "publisher", "first-page": "2436", "journal-title": "Immunity", "key": "bib2", "volume": "55", "year": "2022" }, { "DOI": "10.1136/thoraxjnl-2017-210289", "article-title": "Local dornase alfa treatment reduces NETs-induced airway obstruction during severe RSV infection", "author": "Cortjens", "doi-asserted-by": "publisher", "first-page": "578", "journal-title": "Thorax", "key": "bib3", "volume": "73", "year": "2018" }, { "DOI": "10.12788/jhm.3560", "article-title": "Early and significant reduction in C-reactive protein levels after corticosteroid therapy is associated with reduced mortality in patients with COVID-19", "author": "Cui", "doi-asserted-by": "publisher", "first-page": "142", "journal-title": "Journal of Hospital Medicine", "key": "bib4", "volume": "16", "year": "2021" }, { "DOI": "10.1016/j.mcpro.2021.100113", "article-title": "Proteome profiling of recombinant dnase therapy in reducing NETs and aiding recovery in COVID-19 patients", "author": "Fisher", "doi-asserted-by": "publisher", "journal-title": "Molecular & Cellular Proteomics", "key": "bib5", "volume": "20", "year": "2021" }, { "DOI": "10.1016/S2213-2600(21)00460-4", "article-title": "Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial", "author": "Fisher", "doi-asserted-by": "publisher", "first-page": "255", "journal-title": "The Lancet. Respiratory Medicine", "key": "bib6", "volume": "10", "year": "2022" }, { "DOI": "10.1016/j.jaci.2020.09.018", "article-title": "IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study", "author": "Galván-Román", "doi-asserted-by": "publisher", "first-page": "72", "journal-title": "The Journal of Allergy and Clinical Immunology", "key": "bib7", "volume": "147", "year": "2021" }, { "DOI": "10.1080/22221751.2020.1770129", "article-title": "Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors", "author": "Han", "doi-asserted-by": "publisher", "first-page": "1123", "journal-title": "Emerging Microbes & Infections", "key": "bib8", "volume": "9", "year": "2020" }, { "DOI": "10.1016/j.jaci.2020.05.008", "article-title": "Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19", "author": "Herold", "doi-asserted-by": "publisher", "first-page": "128", "journal-title": "The Journal of Allergy and Clinical Immunology", "key": "bib9", "volume": "146", "year": "2020" }, { "DOI": "10.3389/fimmu.2021.714833", "article-title": "Non-randomized trial of dornase alfa for acute respiratory distress syndrome secondary to covid-19", "author": "Holliday", "doi-asserted-by": "publisher", "journal-title": "Frontiers in Immunology", "key": "bib10", "volume": "12", "year": "2021" }, { "DOI": "10.1056/NEJMoa2021436", "article-title": "Dexamethasone in hospitalized patients with Covid-19", "author": "Horby", "doi-asserted-by": "publisher", "first-page": "693", "journal-title": "The New England Journal of Medicine", "key": "bib11", "volume": "384", "year": "2021" }, { "DOI": "10.1038/s41467-022-32320-1", "article-title": "Microbe capture by splenic macrophages triggers sepsis via T cell-death-dependent neutrophil lifespan shortening", "author": "Ioannou", "doi-asserted-by": "publisher", "journal-title": "Nature Communications", "key": "bib12", "volume": "13", "year": "2022" }, { "DOI": "10.1016/j.jcf.2011.10.003", "article-title": "Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis", "author": "Konstan", "doi-asserted-by": "publisher", "first-page": "78", "journal-title": "Journal of Cystic Fibrosis", "key": "bib13", "volume": "11", "year": "2012" }, { "DOI": "10.1007/s15010-020-01464-x", "article-title": "Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19)", "author": "Kurth", "doi-asserted-by": "publisher", "first-page": "619", "journal-title": "Infection", "key": "bib14", "volume": "48", "year": "2020" }, { "DOI": "10.1007/978-3-030-00710-2", "author": "Lazarus", "doi-asserted-by": "publisher", "first-page": "471", "key": "bib15", "volume-title": "Pharmaceutical Biotechnology: Fundamentals and Applications", "year": "2019" }, { "DOI": "10.1016/j.jcv.2020.104370", "article-title": "Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19", "author": "Liu", "doi-asserted-by": "publisher", "journal-title": "Journal of Clinical Virology", "key": "bib16", "volume": "127", "year": "2020" }, { "DOI": "10.1093/cid/ciaa641", "article-title": "Prognostic value of c-reactive protein in patients with coronavirus 2019", "author": "Luo", "doi-asserted-by": "publisher", "first-page": "2174", "journal-title": "Clinical Infectious Diseases", "key": "bib17", "volume": "71", "year": "2020" }, { "DOI": "10.1136/bmjebm-2020-111536", "article-title": "Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis", "author": "Malik", "doi-asserted-by": "publisher", "first-page": "107", "journal-title": "BMJ Evidence-Based Medicine", "key": "bib18", "volume": "26", "year": "2021" }, { "DOI": "10.1038/sj.bjc.6602211", "article-title": "The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease", "author": "McArdle", "doi-asserted-by": "publisher", "first-page": "1755", "journal-title": "British Journal of Cancer", "key": "bib19", "volume": "91", "year": "2004" }, { "DOI": "10.1016/j.cels.2020.05.012", "article-title": "Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection", "author": "Messner", "doi-asserted-by": "publisher", "first-page": "11", "journal-title": "Cell Systems", "key": "bib20", "volume": "11", "year": "2020" }, { "DOI": "10.1016/j.xcrm.2020.100144", "article-title": "Inflammatory biomarker trends predict respiratory decline in COVID-19 patients", "author": "Mueller", "doi-asserted-by": "publisher", "journal-title": "Cell Reports. Medicine", "key": "bib21", "volume": "1", "year": "2020" }, { "DOI": "10.1016/j.nmni.2020.100756", "article-title": "Preliminary report of invitro and invivo effectiveness of dornase alfa on SARS-CoV-2 infection", "author": "Okur", "doi-asserted-by": "publisher", "journal-title": "New Microbes and New Infections", "key": "bib22", "volume": "37", "year": "2020" }, { "DOI": "10.1371/journal.pone.0028526", "article-title": "Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving DNase therapy", "author": "Papayannopoulos", "doi-asserted-by": "publisher", "journal-title": "PLOS ONE", "key": "bib23", "volume": "6", "year": "2011" }, { "DOI": "10.1038/nri.2017.105", "article-title": "Neutrophil extracellular traps in immunity and disease", "author": "Papayannopoulos", "doi-asserted-by": "publisher", "first-page": "134", "journal-title": "Nature Reviews. Immunology", "key": "bib24", "volume": "18", "year": "2018" }, { "DOI": "10.1126/science.aaf3926", "article-title": "Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease", "author": "Pillai", "doi-asserted-by": "publisher", "first-page": "463", "journal-title": "Science", "key": "bib25", "volume": "352", "year": "2016" }, { "DOI": "10.1084/jem.20201012", "article-title": "Neutrophil extracellular traps infiltrate the lung airway,interstitial, and vascular compartments in severe COVID-19", "author": "Radermecker", "doi-asserted-by": "publisher", "journal-title": "Journal of Experimental Medicine", "key": "bib26", "volume": "217", "year": "2020" }, { "DOI": "10.1016/j.healun.2020.03.012", "article-title": "COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal", "author": "Siddiqi", "doi-asserted-by": "publisher", "first-page": "405", "journal-title": "The Journal of Heart and Lung Transplantation", "key": "bib27", "volume": "39", "year": "2020" }, { "DOI": "10.1093/eurheartj/ehaa1103", "article-title": "C-reactive protein and clinical outcomes in patients with COVID-19", "author": "Smilowitz", "doi-asserted-by": "publisher", "first-page": "2270", "journal-title": "European Heart Journal", "key": "bib28", "volume": "42", "year": "2021" }, { "DOI": "10.1016/j.eclinm.2021.101152", "article-title": "Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial", "author": "Tornling", "doi-asserted-by": "publisher", "journal-title": "EClinicalMedicine", "key": "bib29", "volume": "41", "year": "2021" }, { "DOI": "10.1016/j.celrep.2020.107602", "article-title": "Histones, DNA, and citrullination promote neutrophil extracellular trap inflammation by regulating the localization and activation of TLR4", "author": "Tsourouktsoglou", "doi-asserted-by": "publisher", "journal-title": "Cell Reports", "key": "bib30", "volume": "31", "year": "2020" }, { "DOI": "10.14740/jocmr4227", "article-title": "Lymphocyte-to-C-reactive protein ratio: a novel predictor of adverse outcomes in COVID-19", "author": "Ullah", "doi-asserted-by": "publisher", "first-page": "415", "journal-title": "Journal of Clinical Medicine Research", "key": "bib31", "volume": "12", "year": "2020" }, { "DOI": "10.1371/journal.pone.0256931", "article-title": "Elevated C-reactive protein in early COVID-19 predicts worse survival among hospitalized geriatric patients", "author": "Villoteau", "doi-asserted-by": "publisher", "journal-title": "PLOS ONE", "key": "bib32", "volume": "16", "year": "2021" }, { "DOI": "10.1186/s10020-020-00215-w", "article-title": "Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series", "author": "Weber", "doi-asserted-by": "publisher", "journal-title": "Molecular Medicine", "key": "bib33", "volume": "26", "year": "2020" }, { "DOI": "10.1038/nm.2053", "article-title": "Extracellular histones are major mediators of death in sepsis", "author": "Xu", "doi-asserted-by": "publisher", "first-page": "1318", "journal-title": "Nature Medicine", "key": "bib34", "volume": "15", "year": "2009" }, { "DOI": "10.4049/jimmunol.1003930", "article-title": "Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury", "author": "Xu", "doi-asserted-by": "publisher", "first-page": "2626", "journal-title": "Journal of Immunology", "key": "bib35", "volume": "187", "year": "2011" }, { "DOI": "10.1016/S0140-6736(20)30566-3", "article-title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study", "author": "Zhou", "doi-asserted-by": "publisher", "first-page": "1054", "journal-title": "Lancet", "key": "bib36", "volume": "395", "year": "2020" }, { "DOI": "10.1172/jci.insight.138999", "article-title": "Neutrophil extracellular traps in COVID-19", "author": "Zuo", "doi-asserted-by": "publisher", "journal-title": "JCI Insight", "key": "bib37", "volume": "01", "year": "2020" } ], "reference-count": 37, "references-count": 37, "relation": { "has-preprint": [ { "asserted-by": "subject", "id": "10.1101/2022.04.14.22272888", "id-type": "doi" } ], "has-review": [ { "asserted-by": "object", "id": "10.7554/eLife.87030.4.sa1", "id-type": "doi" }, { "asserted-by": "object", "id": "10.7554/eLife.87030.4.sa0", "id-type": "doi" }, { "asserted-by": "object", "id": "10.7554/eLife.87030.4.sa3", "id-type": "doi" }, { "asserted-by": "object", "id": "10.7554/eLife.87030.4.sa2", "id-type": "doi" } ], "is-version-of": [ { "asserted-by": "subject", "id": "10.7554/eLife.87030.1", "id-type": "doi" }, { "asserted-by": "subject", "id": "10.7554/eLife.87030.2", "id-type": "doi" }, { "asserted-by": "subject", "id": "10.7554/eLife.87030.3", "id-type": "doi" } ] }, "resource": { "primary": { "URL": "https://elifesciences.org/articles/87030" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial", "type": "journal-article", "update-policy": "http://dx.doi.org/10.7554/elife.87030.4", "volume": "12" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit